Dr. Alex Shih-Min Huang joined BeiGene in April 2021 and is the Vice President, Head of Cell Therapy. He is an experienced leader of science and people with substantial proficiency in drug discovery and development. Prior to joining BeiGene, Dr. Huang had close to 20 years of industrial experience at Novartis, Sanofi, Genentech, BMS, and AbbVie, with increasing responsibility. During those years, he led teams and advanced programs through R&D milestones that span from target ID/validation to life cycle management. His pipeline experience encompasses diverse therapeutic modalities, including cell therapy, and targets broad biological space, including immuno-oncology, apoptosis, and B cell signaling pathways in both solid tumors and hematological malignancies.

Dr. Huang obtained his doctoral degree in Microbiology and Immunology from the University of Rochester Medical Center and completed his post-doctoral training at the Genomics Institute of the Novartis Research Foundation (GNF) in San Diego.